Maintaining optimal lung capacity is crucial for overall health, especially as we age or face respiratory conditions.
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in ...
The levels of PCSK6 are not associated with worse respiratory outcomes in patients with mixed fibrotic interstitial lung disease.
Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback.Company plans to submit IND in June 2026 for ...
inews.co.uk on MSNOpinion
This is how the world will look after Trump
Americans are tired of wars and shouldering the responsibility of others ...
Exercise capacity and quality of life improved for children with chronic respiratory disease with pulmonary rehabilitation, ...
Rudy Giuliani is hospitalized in critical condition and "is recovering from pneumonia" after being on a ventilator, his spokesman said. The 81-year-old former New York City mayor is critical but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results